The Long-acting Basal
This presentation is the property of its rightful owner.
Sponsored Links
1 / 1

For any questions, please contact Hanmi Pharm. Co., Ltd., PowerPoint PPT Presentation


  • 140 Views
  • Uploaded on
  • Presentation posted in: General

The Long-acting Basal I nsulin ( LAPS Insulin 115) O ffers O nce-weekly D osing P otential W ith Favorable PK, PD And M itogenic Profiles. P933. IY Choi 1 , SY Hwang 1 , , JY Kim 1 , SY Jung 1 , DJ Kim 1 , YM Lee 1 , YH Kim 1 , M Trautmann 2 , M Hompesch 2 , JW Son 1 , SC Kwon 1

Download Presentation

For any questions, please contact Hanmi Pharm. Co., Ltd.,

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


For any questions please contact hanmi pharm co ltd

The Long-acting Basal Insulin (LAPSInsulin 115) Offers Once-weekly Dosing Potential

With Favorable PK, PD And Mitogenic Profiles

P933

IY Choi1, SY Hwang1, , JY Kim1, SY Jung1, DJ Kim1, YM Lee1, YH Kim1, M Trautmann2, M Hompesch2, JW Son1, SC Kwon1

1Hanmi Pharm. Co., Ltd., Seoul, South Korea, 2Profil Institute, Chula Vista, CA, USA

RESULTS

  • PK matched with weekly GLP-1 for combination therapy

  • Longer half-life

  • Flat profile

  • Low Variability (intra-patient)

BACKGROUND

PK/PD Correlation and Dose Sparing Effect

  • Low Risk of hypos

  • Flexible timing/dosing

  • Little or no weight gain

Figure 3. PK in normal and renal failure model rats

  • LAPSInsulin 115 as a once weekly basal insulin

In vitro Binding, Proliferation, and ex vivo T Cell Activation

IGF-1R phosphorylation

(a) PK in normal rats (n=5, s.c.)

Insulin 115 analog conjugated with a constant region of a human immunoglobulin fragment via non-peptidyl linker.

Table 1. Receptor binding affinity, metabolic and mitogenic potencies relative to human insulin

4 foldreduced dose

Additional requirements

  • Excellent Device

  • No CV safety concerns

  • Lower peak-to-trough ratio from long duration of action

  • Improved patient adherence by once-weekly administration

  • Ideal combination partner with weekly GLP-1 agonist[EASD 2014 Poster #972, Combination of LAPSInsulin 115 and LAPSCA-Exendin-4]

*

**

-1.0

***

-1.8

-2.0

***

***

-2.6

-3.3

-3.4

  • Key requirements for once weekly insulin

ERK1/2 phosphorylation

*p<0.05, **p<0.01 vs vehicle by Anova test

AKT phosphorylation

§Metabolic potencies were obtained from lipogenesis assay from rat primary adipocytes

  • Both LAPSInsulin 115 and Insulin 115 showed reducedaffinities on IR and IGF-1R compared with human insulin. In addition, LAPSInsulin 115 and Insulin 115 showed mitogenic/metabolic potency which was comparable to human insulin.

Human PK and Developmental Plan

Figure 6. Human PK simulation of LAPSInsulin115 by weekly injection

(b) PK comparison in normal and renal failure model rats (n=5, s.c.)

Figure 7. Development plan of LAPSInsulin 115 and QUANTUM project

Insulin

(172 nmol/kg, sc)

Singleweek Profile

Weekly injected steady state profile

Insulin 115

(172 nmol/kg, sc)

LAPSInsulin 115

(22.3 nmol/kg, sc)

LAPSInsulin115, t1/2= 132 hrs

Weekly Peak-to-Trough Ratio = 1.6

AIMS

LAPSInsulin115,

Daily Peak-to-Trough Ratio =~1.1

Immunogenic threshold

  • Investigation of in vitro receptor pharmacology, metabolic, and mitogenic activity of LAPSInsulin 115

  • Evaluation of pharmacokinetics and pharmacodynamics of LAPSInsulin 115 in normal and diabetic animal models

  • Prediction of human pharmacokinetic profile of LAPSInsulin 115 based on animals’ PK data

8%

LAPSInsulin,

Daily Peak-to-Trough Ratio =~1.3

LAPSInsulin, t1/2= 55 hrs

Weekly Peak-to-Trough Ratio = 4.0

1.1

1.1

1.0

1.1

1.1

1.1

0%

  • QUANTUM is a proprietary name of Hanmi’s diabetes & obesity pipeline

  • Pharmacokinetics in humans was predicted based on PK of three different animals. LAPSInsulin 115 demonstrated extended half-life and lower peak-to-trough ratio than LAPSInsulin. In addition, inter-day variability of LAPSInsulin 115 was ranged from 1.0-1.1.

METHODS

  • LAPSInsulin 115 showed extended half-life compared with LAPSInsulin and daily insulins.

  • LAPSInsulin 115 showed a comparable PK profile in a renal failure rat model (4 mg/kg of cisplatin injected, ip, rats) compared with normal rats.

  • Figure 1. Mitogenic signaling in MCF-7 cells

  • In vitro receptor binding affinity and mitogenic signaling in MCF-7

  • Binding affinity of test materials was measured in competition between unlabeled and 125I-labeled materialson the IR- or IGF-1R/CHO membrane. Mitogenic signaling was assayed in MCF-7 cells and the phosphorylation level was analyzed by Western blot.

Figure 5. Dose-sparing and glucose lowering in db/db mice (n=7, s.c.)

Figure 4. PK/PD in pigs (n=3, s.c.)

CONCLUSIONS

(a) Singledose

  • In vitrobiological properties showed that Insulin 115 and LAPSInsulin 115 did not increase the mitogenic potency when compared with insulin.

  • An extended PK profiles and prolonged glucose lowering efficacies suggest that LAPSInsulin 115 may achieve a basal insulin profile suitable for once weekly use.

  • The extended human PK modeling suggests that LAPSInsulin 115 is an ideal combination partner with LAPSCA-Exendin-4 [EASD 2014 Poster #972].

  • Ex vivo T cell activation (Antitope limited, UK)

  • Test articles were incubated for 8 days with PBMC from 50 donors. Cell proliferation was meausred by [3H]-Thymidine incorporation and T-cell activation was identified with IL-2 secretion by Elispot assay.

LAPS Insulin 115

t1/2 = 76.6 hrs

Figure 2. Ex vivo T cell activation of Insulin 115 and LAPSInsulin 115

IGF-1 receptor signaling

Insulin 115

Asp B10

IGlargine

h-Insulin

Control

IGF-1

Insulin

IGF-1

(b) 4-week repeated dose

  • Pharmacokinetic analysis of LAPSInsulin 115 in animal models

  • Test materials were s.c. injected to normal or renal failure SD rats or normal pigs. Renal failure SD rat model was induced by 4 mpk of cisplatin. Serum concentration of test articles were determined using ELISA and PK parameters were calculated by a non-compartmental method.

p-IGF-1R

LAPSInsulin115

t1/2 = 44.1 hrs

6 fold

reduced dose

IGF-1R

IGF-1R

p-AKT

IRS-1/2

SHC

LAPS Insulin

t1/2 = 23 hrs

AKT

PI3K

RAS/RAF

  • Phamacodynamic analysis of LAPSInsulin 115 in db/db mice

  • In an acute study, 4-hr fasting blood glucose level was measured every day after s.c administration of test articles in db/db mice. In a chronic study, HbA1c level was measured after 4-wk administration in db/db mice with Q2D dosing interval to mimic human QW dosing.

p-ERK1/2

AKT

ERK1/2

ERK1/2

Apoptosis

Cell proliferation

Actin

LAPSInsulin

t1/2 = 18.5 hrs

IDeg

t1/2 = 2.9 hrs

20K PEG Insulin

t1/2 = 6.7 hrs

  • Pharmacokinetic prediction in human

  • Human serum concentration-time was predicted by Css-MRT method from PK parameters of mice, rats and dogs. Human CL was derived from rule of exponent methods, and human Vd was from allometry applied correction factor.

REFERENCES

  • LAPSInsulin 115 showed prolonged glucose lowering effect compared to LAPSInsulin in db/db mice at the same dose and even with a 6 fold lower dose.

  • LAPSInsulin 115 achieved a similar HbA1c reduction with a 4 fold lower dose.

  • Insulin 115 showed negligible activation of T cells from 50 human donors, which is below the immunogenic threshold. In addition, LAPSInsulin 115 completely attenuated the residual T cell activation.

1. Diabetic Medicine (2013) 30: 1293–1297., 2. Diabetes (2011) 60 (Suppl. 1):LB11 (37-LB)

3. PLoS ONE (2010) 5: e9540., 4. PLoS ONE (2012) 7: e34274.

  • LAPSInsulin 115 showedPK/PD correlation in normal pigs.

  • Insulin 115 triggered mitogenic signals comparable with human insulin, whereas positive controls (IGF-1 and AspB10) showed significantly higher mitogenic signals.

For any questions, please contact Hanmi Pharm. Co., Ltd.,

Phone: +82-31-371-5141; [email protected]

Hanmi Pharm. Co., Ltd.

European Association for the Study of Diabetes 50th Annual Meeting; Vienna, Austria; September 15-19, 2014

Hanmi


  • Login